The oligonucleotide synthesis market is estimated to be worth $2.2 billion and is expected to grow at CAGR of 17.8% during the forecast period.

Read More: https://www.rootsanalysis.com/reports/oligonucleotide-synthesis/304.html

Post the marketing of Vitravene®, the first antisense oligonucleotide-based therapy to receive approval (in 1998), various stakeholders have undertaken multiple research initiatives to verify the potential of oligonucleotides as therapeutic agents. The known applications of oligonucleotides in research and diagnostics, in addition to their therapeutic use, have significantly increased. It is worth mentioning that these molecules play a crucial role in genetic testing, molecular testing protocols and various analytical testing procedures, such as artificial gene synthesis and polymerase chain reaction. In fact, several preclinical and clinical studies have demonstrated the potential of oligonucleotides as a safe and effective treatment modality, owing to their unique characteristics, such as high target specificity and superior pharmacokinetic profile.